Skip to main content
English
Català
Español
Company
Overview & History
Team
Join Oryzon
Epigenetics
Histone Code Hypothesis
Modulator Enzymes
LSD1 & Disease
Technology Platforms
Scientific Publications by Oryzon
Therapeutic Programs
Strategy
LSD1 & Cancer
Oryzon's Pipeline
Collaborative Research
Collaborative Projects
For Patient
Patient Information
Shareholders and Investors
Investor Information and News
Share Information
Events & Presentations
Financial Information & Downloads
Analyst Coverage
Corporate Governance
Corporate Social Responsibility
News & Press Releases
Contact
General Contact
Investor Contact
Email Alerts
News
Archive
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
News & Press Releases
5 February 2018
ORYZON Appoints Clinical Development Leader Lori A. Kunkel, M.D., as a Scientific Advisor
29 January 2018
ORYZON announces First Patient In in ORY-2001 MS Phase IIA trial SATEEN and presents new data on ORY-2001 at the third annual ACTRIMS Forum 2018 in San Diego
23 January 2018
ORYZON to present at two US investor conferences
4 January 2018
ORYZON to present at the Neuroscience Innovation Forum in San Francisco
4 December 2017
Preclinical Efficacy Data on Sickle Cell Disease of ORY-3001, a LSD1 inhibitor from ORYZON, to be presented at ASH 2017
13 November 2017
ORYZON to present new preclinical data of ORY-2001 at the Neuroscience 2017 meeting organized by the Society for Neuroscience
7 November 2017
ORYZON Reports Financial Results and Corporate Update for the 3rd Quarter Ended September 30, 2017
2 November 2017
ORYZON to participate in three scientific meetings on CNS
31 October 2017
ORYZON receives approval from AEMPS to start SATEEN: a Phase IIA clinical trial in Multiple Sclerosis with ORY-2001
9 October 2017
ORYZON to present new data on its anti-neurodegenerative drug ORY-2001 at the International Conference on Multiple Sclerosis ECTRIMS-ACTRIMS
Pages
« first
‹ previous
…
2
3
4
5
6
7
8
9
10
…
next ›
last »